Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions. [electronic resource]
Producer: 20200622Description: 209-216 p. digitalISSN:- 1524-4733
- Aged
- Anticholesteremic Agents -- adverse effects
- Cross-Sectional Studies
- Databases, Factual
- Drug Costs
- Drug Prescriptions
- Eligibility Determination -- economics
- Female
- Formularies as Topic
- Health Care Rationing -- economics
- Health Services Accessibility -- economics
- Humans
- Insurance Coverage -- economics
- Insurance, Pharmaceutical Services -- economics
- Male
- Medicare -- economics
- Middle Aged
- PCSK9 Inhibitors
- Prior Authorization -- economics
- Serine Proteinase Inhibitors -- adverse effects
- Time Factors
- United States
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.